
Contents

<i>Editors</i>	vii
<i>Contributors</i>	vii
<i>Preface</i>	xi
Section I: First line anti-inflammatory and bronchodilator drugs	
1 Novel mechanistic aspects of glucocorticosteroids in relation to asthma therapy <i>I. M. Adcock</i>	1
2 Benefit–risk assessment of long-acting β -adrenergic and ultra long-acting β -adrenergic agonists <i>M. Cazzola, J. Lötvall, M. G. Matera</i>	17
3 Non-bronchodilator activities of β_2 -agonists <i>N. A. Hanania</i>	31
4 The pros and cons of combination therapy <i>J. Lötvall</i>	47
Section II: Novel approaches to bronchodilation	
5 Controversies surrounding antileukotrienes <i>S. Salvi</i>	59
6 The role of phosphodiesterase-4 inhibitors in asthma <i>G. P. Currie, D. K. C. Lee</i>	67
7 Anticholinergic agents in asthma <i>J. Christian Virchow, M. Lommatzsch</i>	79
Section III: Immunomodulation	
8 Anti-IgE monoclonal antibody: a new era in the treatment of allergic asthma? <i>C. Oliveri, R. Polosa, G. D'Amato</i>	91
9 New frontiers in allergen immunotherapy for asthma <i>R. Polosa</i>	105

10	Role of CpG DNA in asthma <i>D. Gor, J. N. Kline</i>	111
11	Putative role of antimicrobial activity in the treatment of asthma <i>P. Tarsia, S. Aliberti, M. Pappalettera, M. Zanardelli, F. Blasi</i>	123
Section IV: Subphenotype centred therapy		
12	What is new in the management of acute asthma? <i>G. J. Rodrigo</i>	141
13	Airway disease, inflammometry and individualized treatment <i>P. K. Nair, F. E. Hargreave</i>	155
14	Determinants of therapeutic response in asthma: cigarette smoking <i>M. Spears, R. Chaudhuri, N. C. Thomson</i>	165
	<i>Abbreviations</i>	179
	<i>Index</i>	183